Relmada Therapeutics, Inc. (RLMD )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RLMD
- Company Relmada Therapeutics, Inc.
- Price $0.55
- Changes Percentage -20.35
- Change -0.1404
- Day Low $0.55
- Day High $0.65
- Year High $4.47
- Year Low $0.24
- Market Cap $22,902,220
- Price Avg 50 EMA (D) $0.3
- Price Avg 200 EMA (D) $1.88
- Exchange NASDAQ
- Volume 32,688,338
- Average Volume 1,713,816
- Open $0.62
- Previous Close $0.69
- EPS -2.65
- PE -0.26
- Earnings Announcement 2025-05-06 10:59:00
- Shares Outstanding $33,191,623
Company brief: RELMADA THERAPEUTICS, INC. (RLMD )
- Healthcare
- Biotechnology
- Dr. Sergio Traversa M.B.A., Pharm.D.
- https://www.relmada.com
- US
- N/A
- 06-20-2014
- US75955J4022
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.